Sutton Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Sutton Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.74K	Buy	14 +8	+133%	+$1.64K	﹤0.01%	678
2023 Q2	$1.26K	Sell	6 -4	-40%	-$796	﹤0.01%	753
2023 Q1	$2.02K	Buy	10 +4	+67%	+$907	﹤0.01%	644
2022 Q4	$1.31K	Hold	6	–	–	﹤0.01%	1264
2022 Q3	$1.18K	Sell	6 -23	-79%	-$4.96K	﹤0.01%	1253
2022 Q2	$6.21K	Buy	29 +27	+1,350%	+$6.6K	﹤0.01%	1030
2022 Q1	$568	Sell	2 -3	-60%	-$925	﹤0.01%	1462
2021 Q4	$1.88K	Buy	+5	New	+$1.94K	﹤0.01%	1210

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sutton Wealth Advisors's CRL Position: Q3 2023 in Review

Sutton Wealth Advisors increased its Charles River Laboratories (CRL) stake by 133% in Q3 2023, buying an estimated $1.64K and bringing the position to 14 shares worth $2.74K. The position accounts for ﹤0.01% of the portfolio, ranked #678.

Sutton Wealth Advisors first reported a position in CRL in Q4 2021 and has held it in 8 quarters since. The position peaked at $6.21K in Q2 2022. 622 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Sutton Wealth Advisors held 14 shares of Charles River Laboratories worth $2.74K as of Q3 2023.
Sutton Wealth Advisors bought 8 Charles River Laboratories shares in Q3 2023, an estimated $1.64K.
Charles River Laboratories made up ﹤0.01% of Sutton Wealth Advisors's portfolio in Q3 2023, its #678 holding.
Sutton Wealth Advisors first reported a position in Charles River Laboratories in Q4 2021 and has held it in 8 quarters since.
Sutton Wealth Advisors's Charles River Laboratories position peaked at $6.21K in Q2 2022.
622 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Sutton Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.